 
Safety of Furosemide in Premature Infants at Risk of 
Bronchopulmonary Dysplasia  
 
 
Study Protocol  
 
NCT number  [STUDY_ID_REMOVED]  
Document Date as Amended by [CONTACT_423726] V001  09/27/2019  
Document Date Protocol V6.0  03/22/2017  
 
  
NICHD-2014-FUR01  – FUROSEMIDE  Addendum 001   Version  1.0  
IND # [ADDRESS_535278]  Results  
NICHD- 2014- FUR01  
 
Summary:  
This document is an addendum to the Safety of Furosemide in Premature Infants at Risk of 
Bronchopulmonary Dysplasia ( NICHD- 2014 -FUR01 ) protocol . The purpose of this addendum 
is to collect additional hearing test  results from the subset of FUR01 participants who meet the 
eligibility criteria  outlined below . We will record results from hearing tests  that were conducted 
as part of standard care after completion of final FUR01 study assessments up to and including 
when the participant passes a hearing test  (both ears) , or until the participant reached  [ADDRESS_535279]. 
 
Rational e: 
Infants born prematurely  with documented fai led or equivocal hearing tests typi[INVESTIGATOR_423695] -up testing  as part of their routine medical care through the first year of life. Follow -up 
testing typi[INVESTIGATOR_423696] a substantial number of these infants have normal hearing. Results 
of these follow -up hearing tests in FUR01 participants with a failed or equivocal hearing test 
reported at final study assessments prior to discharge,  are important to collect to add to the 
safety profile of furosemide in previously premature infants at risk of b ronchopulmonary 
dysplasia.  
 
Inclusion Criteria:  
1. Participat ed in the FUR01 Study  
2. Documented hearing test result (for either ear ) was categorized as fail or equivocal at 
final FUR01 study assessments  reported prior to discharge  
3. Document ed informed consent, or waiver of informed consent, as determined by [CONTACT_423727]:  
1. Informed consent was withdrawn during FUR01 study participation 
 Events of Interest:
 
Failed hearing test  (in either ear) identified by  [CONTACT_423728] (e.g. BAER) , as 
determined by [CONTACT_423729] . 
 
 
NICHD-2014-FUR01  – FUROSEMIDE  Addendum 001   Version  1.0  
IND # 120933  27 September 2019  
 
CLIENT CONFIDENTIAL  Follow -Up Hearing Assessment  / Data Collection 
 
For eligible participants , the study staff will continue to collect results from standard of care 
hearing tests , if available, until and including when the participant passes a hearing test 
(both ears) or until the participant is [ADDRESS_535280] review .  
 
Analysis Plan:  
The analyses described in the  protocol  and Statistical Analysis Plan  will be conducted using the 
follow -up hearing test results.  
NICHD-2014-FUR01  – FUROSEMIDE     Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
 
 
Pediatric Trials Network  
 
Safety of Furosemide in Premature Infants  at Risk of Bronchopulmonary 
Dysplasia  
 
NICHD- 2014- FUR01  
 
Phase 2 Trial 
 
 
Funding Sponsor:  
The Eunice Kennedy Shriver National Institute of Child Health and 
Human Development (NICHD)  
 
Funding Mechanism:  Task Order  
Protocol Date:  22-Mar-2017 
Protocol Version:  6.0  
IND Number:  120,933 
Principal Investigator (IND Sponsor):  
 Matthew M. Laughon, MD, MPH  
[CONTACT_271701] of North Carolina at Chapel Hill  
Chapel Hill, NC [ZIP_CODE] -7596 
Office : [PHONE_8787] 
E-mail: [EMAIL_5274]  
 
 ____________________________________________________________________________________________  
 
NICHD-2014-FUR01  – FUROSEMIDE     Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
 
Statement of Compliance  
 
This trial will be conducted in compliance with the protocol, International Conference on 
Harmoni sation (ICH) guideline E6: Good Clinical Practice (GCP) : Consolidated Guideline, and 
the applicable regulatory requirements from the [LOCATION_002] Code of Federal Regulations 
(CFR) , including 45 CFR 46 (human subjects protection), 21 CFR 312 (Investigational New 
Drug), 21 CFR part 50 (informed consent) , and 21 CFR part 56 (institutional review board [ IRB]) 
as well as international  regulatory requirements if  applicable.  
 
All individuals responsible for the design and/or conduct of this study have completed Human 
Subjects Protection Training and are qualified to be conducting this research.  
  
 ____________________________________________________________________________________________  
i 
NICHD-2014-FUR01  – FUROSEMIDE     Version 6.0 
IND # [ADDRESS_535281] of this study as outlined herein and will make 
a reasonable effort to complete the study within the time designated. I agree to make all reasonable efforts to adhere to the attached protocol.  
 
I will provide all study personnel under  my supervision with copi[INVESTIGATOR_88472]’s representative.  I will discuss this 
material with study personnel to ensure that they are fully informed about the effectiveness and 
safety p arameters and the conduct of the study in general. I am aware that, before beginning 
this study, the institutional review board responsible for such matters must approve this protocol 
in the clinical facility where it will be conducted.  
 
I agree to provide all participant s with informed consent forms, as required by [CONTACT_271662]. I further agree to report to the sponsor 
or its representative any adverse events in accordance with the terms of this protocol and the 
U.S. Code of Federal Regulations, Title 21, part 312.64 as well as international regulatory 
requirements if applicable.  
 
 
   
Principal Investigator [CONTACT_5627] ( Print)  
   
   
Signature   [CONTACT_1782]  
  
 ____________________________________________________________________________________________  
ii 
NICHD-2014-FUR01  – FUROSEMIDE     Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
 
STUDY PRINCIPAL INVESTIGATOR / IND SPONSOR SIGNATURE  
 
[CONTACT_271699] 
(e.g., package inserts), and provides the necessary assurances that this clinical study will be 
conducted according to all stipulations of the protocol, including al l statements regarding 
confidentiality and according to local legal and regulatory requirements and to the principles 
outlined in applicable U.S. federal regulations and ICH guidelines.  
 
 
Matthew M. Laughon, MD, MPH    
Pediatric Trials Network Study Principal  
Investigator [INVESTIGATOR_423697]  
 ____________________________________________________________________________________________  
iii 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535282] of Abbreviations  .................................................................................................................. vii 
Protocol S ynopsis  ...................................................................................................................…ix  
 
[ADDRESS_535283] been 4 studies of the pharmacokinetics of furosemide in 
premature infants.  ..................................................................................... 16 
2.3 Potential Risks and Benefits  ................................................................................. 19 
2.3.1  Potential Risks  .......................................................................................... 19 
2.3.2  Potential Benefits  ...................................................................................... 19 
3 Objectives  ........................................................................................................................ 20 
3.1 Study Outcome Measures  .................................................................................... 20 
3.1.1  Primary Outcome Measures  ...................................................................... 20 
3.1.2  Secondary Outcome Measures  .................................................................  20 
3.1.3  Other safety and efficacy outcomes  .......................................................... 20 
4 Study Design  .................................................................................................................... 22 
5 Study Population .............................................................................................................. 23 
5.1 Selection of the Study Population ......................................................................... 23 
5.2 Inclusion/Exclusion Criteria ................................................................................... 23 
5.3 Treatment Assignment Procedures  ....................................................................... 23 
5.3.1  Additional Participants  ............................................................................... 23 
5.3.2  Randomization Procedur es ....................................................................... 24 
5.3.3  Masking Procedures  .................................................................................. 24 
5.3.4  Reasons for Participant Withdrawal  ........................................................... 24 
5.3.5  Termination of Study  ................................................................................. 25 
6 Study procedures  ............................................................................................................. 26 
6.1 Summary of Procedures  ....................................................................................... 26 
6.2 Screening ............................................................................................................. 26 
6.3 Enrollment/Baseline  .............................................................................................. 26 
6.4 Treatment Period  .................................................................................................. 27 
6.5 Follow-up Period ................................................................................................... 27 
6.6 36-week PMA Assessment  ................................................................................... 27 
6.7 Final Study Assessment  ....................................................................................... 28 
6.8 Respi[INVESTIGATOR_423698]  ....................................................................................... 28 
6.9 Laboratory Evaluations  ......................................................................................... 28 
 ____________________________________________________________________________________________  
iv 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535284] Description ................................................................................................ 31 
7.1 Dosage and Study Drug Information  ..................................................................... 31 
7.2 Formulation, Packaging, and Labeling .................................................................. 32 
7.3 Preparation and Administration of Study Intervention/Investigational Product  ....... [ADDRESS_535285] Storage and Stability  ................................................................................ 32 
7.5 Concomitant Medications/Treatments  ...................................................................  32 
8 Assessment of Safety  ....................................................................................................... 34 
8.1 Methods and Timing for Assessing, Recording and Analyzing Safety Parameters  34 
8.1.1  Adverse Event  ........................................................................................... 34 
8.1.2  Unexpected Adverse Event  ....................................................................... 34 
8.1.3  Identification of Events and Timeframe for Reporting ................................ 34 
8.1.4  Follow -up of Adverse Events  ..................................................................... 35 
8.1.5  Guidelines for Assessing Intensity of an Adverse  Event  ............................ 35 
8.1.6  Guidelines for Determining Causality ......................................................... 35 
8.1.7  Discontinuation of a Participant Due to Adverse Events  ............................ 35 
8.1.8  Reportin g Procedures  ............................................................................... 36 
8.2 Serious Adverse Events  ........................................................................................ 36 
8.3 Regulatory Reporting ............................................................................................  36 
8.4 Safety Oversight  ................................................................................................... 36 
8.5 Dose  Escalation and Halting Criteria: Safety Concerns  ......................................... 36 
9 Clinical Monitoring  ............................................................................................................ 38 
10 Statistical Considerations  .................................................................................................  39 
10.1  Study Endpoints  .................................................................................................... 39 
10.2  Sample Size Considerations  ................................................................................. 39 
10.3  Interim Safety Analysis  ......................................................................................... 39 
10.4  Analysis Plan  ........................................................................................................ 39 
11 Participant Confidentiality  .................................................................................................  41 
12 Informed Consent Process  ............................................................................................... 42 
13 Source Documents and Access to Source Data/Documents  ............................................ 43 
14 Quality Control and Quality Assurance  ............................................................................. 44 
15 Ethics/Protection of Human Participants  ........................................................................... [ADDRESS_535286] Keepi[INVESTIGATOR_007] ................................................................................. 47 
 ____________________________________________________________________________________________  
v 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
Table of Contents continued  
 
16.1  Data Management Responsibilities  ....................................................................... 47 
16.2  Data Capture Methods  .......................................................................................... 47 
16.3  Timing/Reports  ..................................................................................................... 47 
16.4  Study Records Retention  ...................................................................................... 48 
16.5  Protocol Deviations  ............................................................................................... 48 
16.6  Participant Privacy/Authorization  .......................................................................... 48 
17 Publication Policy  ............................................................................................................. 49 
18 Appendix A: Laboratory Values  ........................................................................................ 50 
19 Literature References  ....................................................................................................... 51 
 
 ____________________________________________________________________________________________  
vi 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535287]  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmoni sation  
ICMJE  International Committee of Medical Journal Editors  
IDES  Internet Data Entry System  
IEC Independent or Institutional Ethics  Committee  
IND Investigational New Drug Application  
IRB Institutional Review Board  
IV Intravenous  
K Potassium  
Kg Kilogram  
L Liter 
LPM Liters  per Minute  
MedDRA  Medical Dictionary for Regulatory Activities  
Mg Milligram  
mcg Microgram  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_33891])  
Na Sodium  
NCPAP  Nasal Continuous Positive Airway Pressure  
NICU  Neonatal Intensive Care Unit  
 ____________________________________________________________________________________________  
vii 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535288] of Abbreviations –  continued  
 
NIH National Institutes of Health  
NRN  Neonatal Research Network  
PDA Patent Ductus Arteriosis  
PI [INVESTIGATOR_328186]  (gestational age plus postnatal age ) 
PK Pharmacokinetics  
PO By [CONTACT_423730], Normal T Cell Expressed & Secreted  
SAE Serious Adverse Event  
TORO  Transfer of Regulatory Obligations  
t1/2 Half-life 
Vss Volume of distribution at steady state  
WHO  World Health Organization  
 
 
 ____________________________________________________________________________________________  
viii 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
Protocol Synopsis  
Protocol Title : Safety of Furosemide in Premature Infants at Risk of 
Bronchopulmonary Dysplasia (BPD)  
Phase : 2 
Produc t: Furosemide  
Objectives:  Primary:  Describe the safety of furosemide in pr emature infants at risk of 
BPD 
Secondary: Preliminary effectiveness and pharmacokinetics (PK) of 
furosemide  
Study Design: Multi -center, randomized, placebo -controlled , dose escalating , double 
masked , safety study   
Study Population:  Inclusion Criteria  
1. Documented i nformed consent from legal guardian , prior to study 
procedures   
2. Receiving positive airway pressure (nasal continuous airway 
pressure, nasal intermittent positive pressure ventilation, or nasal 
cannula flow > 1LPM) or mechanical ventilation (high frequency or 
conventional)  at time of randomization.  
3. < 29 weeks gestational age  at birth  
4. 7-28 days postnatal age  at time of randomization  
Exclusion Criteria  
1. Exposure to any diuretic ≤ 72 hours prior to randomization  
2. Previous enrollment and dosing in current study, “ Safety of 
Furosemide in Premature Infan ts at Risk of Bronchopulmonary 
Dysplasia ” 
3. Hemodynamically significant p atent ductus arteriosus , as 
determined by [CONTACT_093]  
4. Major congenital anomaly (e.g. congenit al diaphragmatic hernia, 
congenital pulmonary adenomatoid malformation)  
5. Meconium aspi[INVESTIGATOR_1518]  
6. Known a llergy to any diuretic  
7. Serum creatinine >1.7 mg/dl  < 24 hours prior to randomization  
8. BUN >50  mg/dl  < 24 hours prior to randomization  
9. Na <125 mmol/L < 24 hours prior to randomization  
10. K ≤2.5 mmol/L < 24 hours prior to randomization  
11. Ca ≤ 6 mg/dL (or ionized calcium ≤  3.2 mg/dl ) < [ADDRESS_535289] bilirubin >  10 mg/dl < 24 hours prior to randomization *.  
13. Any condition which would make the participant , in the opi[INVESTIGATOR_13046], unsuitable for the study . 
 
*If total bilirubin is measured without the differentiated (conjugated 
(direct) and unconjugated (indirect)  fractions and is ≤10mg/dl, this 
value can be accepted for determination of indirect bilirubin ≤10mg/dl.  
Number of Participants:  120 
Number of Sites:  Approximately 30 sites 
Duration of 
Participation:  Up to 35 days (28 days of study drug plus 7 days of safety monitoring). 
Information about hospi[INVESTIGATOR_423699] [ADDRESS_535290] 
menstrual age and /or at discharge.  
 ____________________________________________________________________________________________  
9 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
Dose Schedule:  Table . N and dosing scheme  
  N Furosemide  
(IV) Furosemide  
(enteral)  N Cohort  
N 
Cohort  1 Placebo  10 1 mg/kg q 24 
hours  2 mg/kg q 24 
hours  30 40 
Cohort  2 Placebo  10 1 mg/kg q 6 
hours  2 mg/kg q 6 hours  30 40 
Cohort  3 Placebo  10 2 mg/kg q 6 
hours  4 mg/kg q 6 hours  30 40 
 
 
 
 ____________________________________________________________________________________________  
10 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535291] : 
 
Study Principal Investigator / Matthew M. Laughon, MD, MPH  
IND Sponsor :  [CONTACT_423758] of North Carolina at Chapel Hill \ 
 Chapel Hill, NC [ZIP_CODE] -7596 
 Telephone: (984) 974 -7851 
 E-mail:  [EMAIL_5274]  
  
 
Study Protocol Chair (Duke PI)  Jason E. Lang, MD, MPH  
 Associate [CONTACT_423759] of Medicine  
 Durham, NC  [ZIP_CODE]  
 Telephone: (919) 684 -8657 
 Email: [EMAIL_1274]  
 
 
Sub-Investigators: Sub-investigators are included in the signature [CONTACT_423757](s) at each clinical site. 
 
 
 
Medical Monitor: Robert Lindblad, MD Chief Medical Officer 
 The Emmes  Corporation 
 [ADDRESS_535292] 
 Telephone: 301 -251-1161  
 Rockville, MD [ZIP_CODE] 
 Email: [EMAIL_6405]  
 
 
BPCA DCC Principal Investigator : [INVESTIGATOR_328191],  PhD  
 Vice President   
 The Emmes  Corporation 
 [ADDRESS_535293] 
 Telephone: 301- 251-1161 
 Fax: 1- [PHONE_5659]  
 Rockville, MD [ZIP_CODE]  
 Email: [EMAIL_8101] 
 
 ____________________________________________________________________________________________  
11 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535294] Officer Representative: David Siegel, MD  
 National  Institutes of Health  
 Eunice Kennedy Shriver  
 National Institute for Child H ealth and Human 
 Development  
 BG 6710B RM 2327D  
 6710B Rockledge Drive 
 Bethesda, MD  [ZIP_CODE]  
 Telephone: 301 -594-8670  
 Fax: 301- 480-3876  
 Email:  [EMAIL_8102]   
 
 ____________________________________________________________________________________________  
12 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535295] (BPCA) mandates the National Institutes of Health 
(NIH) to prioritize thera peutic areas in critical need for pediatric labeling, sponsor pediatric 
clinical trials, and submit these data to FDA for consideration for labeling changes.  This study 
will be conducted in accordance with Section 409l of the Public Health Service Act; as  such, the 
results from this research may be submitted to the FDA for review and use in negotiated labeling changes.  This research study is contractually supported by [CONTACT_92434].  The NICHD 
awarded a contract to Duke University  which established a Pediatric Trials Network (PTN) 
through its Duke Clinical Rese arch Institute (DCRI) in order to facilitate trial design for studies 
supported by [CONTACT_4289].  A separate contract was  awarded to The E mmes  Corporation (Rockville, 
MD) to serve as the BPCA Data Coor dinating Center  (DCC) . 
2.2 Scientific Rationale  
Bronchopulmonary dysplasia (BPD) is defined  by [CONTACT_423731], moderate, or severe 
based on required respi[INVESTIGATOR_158728] 36 weeks postmenstrual age .
1 An NIH workshop 
proposed a severity -based definition that classifies BPD into mild, moderate or severe based on 
either postnatal age (PNA)  or postmenstrual age ( PMA ) (Table 2-1). Ehrenkranz et al2 validated 
the NICHD severity -based definition of BPD by [CONTACT_423732] [ADDRESS_535296] -menstrual age (or discharge)  
 
No BPD  Receiving > 21% supplemental oxygen (O 2) for ≤28 days and not at 36 weeks PMA  
Mild BPD  Receiving > 21% O 2 for ≥28 days but not at 36 weeks PMA  
Moderate BPD  Receiving > 21% O 2 for ≥28 days  plus treatment with <30% O 2 at 36 weeks PMA  
Severe BPD  Receiving > 21% O 2 for ≥28 days plus ≥30% O 2 and/or positive pressure at [ADDRESS_535297] common pulmonary morbidity associated with 
prematurity and is increasing.  Approximately 50,000 infants are born at ≤ 28 weeks gestational 
age each year in the US and ~35% develop BPD. The incidence of BPD varies widely between 
centers even after adjusting for potential risk factors. Data from [ADDRESS_535298] 
Network shows the rates of BPD vary from 12% to 32%, depending on center, among infants 
born less than 32 weeks gestation. The risi ng number of infants with BPD might be due to the 
 ____________________________________________________________________________________________  
13 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535299] risk factor for BPD is prematurity.  Epi[INVESTIGATOR_423700].18,19 Rojas et al20 identified  low birth weight, presence 
of a patent ductus arteriosus (PDA) as risk factors for BPD in premature infants between 500 and 1000 g. Marshall et al
21 identified gestational age, birth weight, nosocomial infection, fluid 
intake on day 2, PDA, and ventilation at 48 hours of life as risk factors for BPD. A secondary 
analysis of the Neonatal Research Network Glutamine trial identified lower birth weight, lower 
gestational age, male, lower 1 and 5- minute Apgar Scores, higher oxygen requirement at 
24 hours of age, longer duration of assisted ventilation, use of postnatal steroids for BPD , 
presence of severe intraventricular hemorrhage, proven necrotizing enterocolitis, patent ductus 
arteriosus, and late onset sepsis  as risk factors for BPD22 In preterm infants with respi[INVESTIGATOR_423701], the authors found 
that the risk of BPD was associated with lower birth weight, higher oxygen requirement, male 
gender, additional surfactant doses, higher oxygenation index and outborn status.23 Until 
recently, using these risk factors for prediction of BPD has been challenging.23 
 
Accurate prediction of BPD risk is now possible: The NICHD Neonatal Research Network 
recently developed an online, publicly available BPD prediction tool 
(https://neonatal.rti.org/index.cfm?fuseaction=BPDCalculator.start ) (or enter NICHD BPD 
estimator in a search engine)  that accurately predicts the risk of developi[INVESTIGATOR_423702] 7 readily available variables: postnatal day, gestational age, birth weight, sex, 
race/ethnicity, ventilator support, and F iO2. Previous BPD prediction scoring systems have not 
been widely adopted, and each has had significant limitations. Some have satisfactory 
sensitivity and specificity but use a now outdated definition of BPD as oxygen therapy at [ADDRESS_535300] level of BPD or death in more 
than 8 out of 10 cases.  
 
There are no FDA indicated therapi[INVESTIGATOR_423703].   To date, only vitamin A and ca ffeine prevent BPD without known significant long 
term adverse events.35,36  Postnatal steroids reduce BPD, but increase the risk of cerebral 
palsy.37,38  Although inhal ed nitric oxide is beneficial in term infants with hypoxic respi[INVESTIGATOR_696] 
 ____________________________________________________________________________________________  
14 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535301] common by [CONTACT_187237] (93% of diuretic use), in 
premature infants .44 Despi[INVESTIGATOR_423704]’s long history of catastrophic adverse events 
resulting from inadequate study of drugs prior to their widespread use, the majority of drugs 
used in premature infants have undergone insufficient study to receive FDA labeling, including 
diuretics. Extrapolating diuretic safety, effectiveness, and dosing from adults underestimates the complicated physiology of premature infants, who have (1) larger extracellular fluid volume per 
unit body weight, (2) immatur e renal and hepatic function, and (3) a unique blood- brain barrier, 
each of which can alter drug disposition and clearance.
45,46,47 Improper use of drugs in these 
vulnerable patients leads to increased rates of treatment failure, adverse events, mortality, and 
long-term morbidities.47 Diuretic studies specific ally designed for premature infants are urgently 
needed.  
 
Furosemide is consistently in the top 10 among all medications reported in all 
hospi[INVESTIGATOR_423705]: We reviewed data from the Pediatrix Data Warehouse from 
2005- 2010 that includes infor mation from ~20% of all infants admitted each year to the NICU in 
the US. Furosemide was the 7th most commonly used drug overall in the NICU from [ADDRESS_535302] commonly used in extremely low birth weight infants (<1000 g; Table 2-2).48 
81 out of every 1000 hospi[INVESTIGATOR_423706].  (668 infant -days per 1000 
infants).  
 
Table  2-2. Most common drugs in the NICU reported from 887,910 infants  
Medication  % exposed  FDA labeling for premature 
 Ampi[INVESTIGATOR_10312]  68 None  
Gentamicin  63 Dosing information  
Caffeine  14 None for <28 weeks  
Vancomycin  9 Dosing information  
Beractant  9 Yes 
Cefotaxime  8 Dosing information  
Furosemide  8 None  
Fentanyl  6 None  
Dopamine  6 None  
Midazolam  5 Yes 
 
 
 
 
 ____________________________________________________________________________________________  
15 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535303] common diuretic used:  Among the 39,357 infants < 32 weeks and <  
1500 g who received diuretics, 93% (36,759) received furosemide ( Table 2-3).44 
Table 2 -3. Infants  <32 weeks and <1500 g exposed to diuretics by [CONTACT_423733]1 N (%)2 Exposure3 Courses3 Days  
of exposure4 
 Total N=39,357     
Furosemide  36,759 (93)  342 784 66 
Spi[INVESTIGATOR_8407]  9577 (24)  86 109 3 
Chlorothiazide  8309 (21)  77 98 29 
Hydrochlorothiazide  2473 (6)  22 26 7 
Bumetanide  1443 (4)  13 17 2 
Acetazolamide  1131 (3)  11 18 2 
1 metolazone (n=147), hydrochlorothiazide/spi[INVESTIGATOR_8407] (n=87), diazoxide (n=64), 
ethacrynic acid (n=61), mannitol (n=8), and amiloride (n=3) exposure was minimal  
2 infants could be exposed to more than one diuretic  
3 per 1000 infants (all infants)  
4 per 1000 infant -days (all infants)  
Furosemide clinical pharmacology :  Furosemide is a loop diuretic that acts in the proximal 
and distal tubules, as well as in the loop of Henle; it inhibits reabsorption of sodium and chloride 
at these sites. Furosemide is indicated in adults and pediatric patients for the treatment of 
edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, 
including the nephrotic syndrome. It is also indicated as adjunctive therapy in acute pulmonary 
edema in adults.  
2.2.[ADDRESS_535304] been 4 studies of the pharmacokinetics of furosemide in premature 
infants.  
Table 2-4. Demographics of premature infants and dosing in furosemide studies  
 N BW GA Postnatal  
age Dose  Route  Frequency of 
administration  
  g weeks  weeks  mg/kg   hours  
Aranda 197849 8 2391+/ -290 35+/-1.8 1.6+/ -0.8 1-1.5 IV Single dose  
Peterson 198050 14 1270+/ -169 30+/-0.8 1.4+/ -0.3 1 IV Single dose  
Vert 198251 8 1326+/ -352 29+/-2 3.1+/ -3 0.29-1.48 IV Single and multiple doses  
Mirochnick 198852 10 829+/ -217 26.6+/ -2.9 2.4+/ -1 1; 2-3 IV; enteral  12 
 
Table 2-5. Pharmacokinetics of furosemide in premature infants  
 Volume of distribution  Clearance   Half -life 
 L/kg ml/kg/hour  hours 
Aranda 197849 0.829+/ -0.118  81.6+/ -15 7.7+/ -1 
Peterson 198050 0.239 +/ -0.027  10.6+/ -2.1 19.9+/ -3 
Vert 198251 0.204+/ -0.075  6.9+/ -5.1 26.8+/ -12.2 
Mirochnick 198852 0.23 +/ - 0.04 1.62-73.8 (range)  1.8-67.3 (range)  
 
 ____________________________________________________________________________________________  
16 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
The use of furosemide varies widely among infants (Table 2 -6) and among centers 
(Figure 2-1): Exposure of premature infants to diuretics varied widely across infants and sites. 
In some centers, the exposure is very high, suggesting that diuretics are used prophylactical ly, 
presumably to prevent BPD. Conversely, in other centers exposure is  rare. These observations 
suggest that there is no universally accepted standard of care for when to expose infants to 
diuretics, and that no exposure is an op tion exercised in some cen ters. 
 
Table [ADDRESS_535305] day of each new diuretic course in infants <32 weeks and <1500 g44 
 No 
support  Nasal  
cannula  HFNC/  
NCPAP  Mechanical 
ventilation  High frequency 
ventilation  FiO2 
 n (%)  n (%)  n (%)  n (%)  n (%)  median, IQR  
furosemide  4886 (6)  12,935 (15)  21,324 (25)  32,811 (39)  12,053 (14)  35 (25, 50)  
spi[INVESTIGATOR_8407]  626 (5)  3336 (29)  4073 (35)  3122 (27)  460 (4)  35 (27, 50)  
chlorothiazide  463 (4)  2867 (27)  3151 (30)  3418 (33)  613 (6) 36 (28, 50)  
hydrochlorothiazide  147 (5)  732 (27)  984 (36)  751 (27)  130 (5)  35 (26, 49)  
bumetanide  18 (1)  43 (2)  98 (5)  853 (47)  813 (45)  45 (30, 75)  
acetazolamide  40 (2)  178 (9)  636 (33)  917 (48)  153 (8)  35 (27, 48)  
HFNC: high flow nasal cannula  
NCPAP: nasal continuous positive airway pressure  
 
Figure 2 -1. Percentage of infants <32 weeks and <1500g exposed to furosemide in 222 
sites of the Pediatrix Medical Group44  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We reviewed the safety and outcomes of infants <  28 weeks born at UNC and Duke from 
2006- 2012: We reviewed infants <  28 weeks gestation and survived >  7 postnatal days at UNC 
and Duke. Traditionally, UNC is a low furosemide exposure site with a high rate of BPD and 
Duke is a high furosemide exposure site with a low rate of BPD. We found that the data 
confirmed this supposition ( Table 2 -7 and Figure 2- 2) — UNC had a 58% furosemide exposure 
with a 60% incidence of death or BPD while Duke had a 95%  furosemide exposure wit h a 
35%% incidence of death or BPD.  UNC infants were most often exposed to 0- 2 mg/kg/day of 
furosemide ( Figure 2- 2) while Duke infants were most often exposed to 4- 6 mg/kg/day of 
furosemide, with 25% exposed to >8 mg/kg/day.  
  
 ____________________________________________________________________________________________  
17 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
Table 2 -7. P remature infants  <28 weeks from 2006-2012 at Duke or UNC NICU  
Characteristics D[LOCATION_006]E UNC  
N 350 329 
Gestational Age(weeks): Median (IQR) 25 (24, 27) 26 (24, 27) 
Birth Weight(grams): Median (IQR) 760 (640, 870) 760 (640, 880) 
Antenatal Steroids: % 92.8% 86.8% 
Surfactan t: % 87.1% 81.7% 
Furosemide: % 94.6% 57.8% 
Maximum Daily Dose(mg/kg/day): Median (IQR) 6.3 (4.2, 8.3) 2.0 (1.9, 2.9) 
Cumulative Dose(mg/kg): Median (IQR) 100.9 (40.3, 191.7) 12.5 (4.3, 39.6) 
 Duration(days): Median (IQR) 33 (14, 54) 7 (3, 26) 
Bronchopulmonary Dysplasia or Death  at 36 Weeks: % 35.4%  59.6%  
Failed Hearing: % 9.1% 3% 
Hypernatremia: % 1.1% 7.3% 
Hyponatremia: % 5.4% 3.3% 
Hyperchloremia: % 19.7% 36.8% 
Hyperkalemia: % 13.1% 15.8% 
Hypokalemia: % 21.4% 11.2% 
High Bicarbonate: % 9.4% 0% 
Low Bicarbonate: % 70.3% 40.7% 
Elevated BUN: %  23.4%  4.60%  
Elevated Creatinine: %  12.9%  1.5%  
Elevated Alkaline Phosphate: %  6.3%  3.6%  
Figure 2 -2. Maximum daily dose of furosemide at UNC and Duke  
 
 
 
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
cBecause the bioavailability of enteral furosemide is approximately 0.5 times that of the intravenous formulation, the enteral + 
intravenous furosemide dose was calculated as:0.5 * enteral dose (mg/kg) + intravenous dose (mg/kg)  0102030405060Percent of premature infants exposed
Maximum daily dose of furosemide (mg/kg/day)UNC
Duke
 ____________________________________________________________________________________________  
18 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
2.3 Potential Risks and Benefits  
2.3.1  Potential Risks  
[IP_ADDRESS]  Risks of Blood  Drawing  
There are small risks to blood sampling, usually some pain/discomfort with the blood stick  and 
blood loss . We will make every effort to avoid additional (to standard of care) sticks for this 
study and will time clinical blood draws to coincide wit h timed samples, using existing 
intravenous lines when possible.  
[IP_ADDRESS]  Furosemide  
Furosemide is associated with water loss and electrolyte depletion. Literature reports indicate 
that premature infants with postmenstrual age <  31 weeks receiving doses exceeding 
1 mg/kg/24 hours may develop plasma levels associated with potential toxic effects including 
ototoxicity. In premature infants,  furosemide may precipi[INVESTIGATOR_423707]/nephrolithiasis.  If 
furosemide is administered to premature infants during the first weeks of life, it may increase the 
risk of persistence of patent ductus arteriosus.  
2.3.2  Potential Benefits  
Furosemide is  used to reduce pulmonary edema, improve pulmonary mechanics, reduce 
exposure to mechanical ventilation , and prevent BPD. Although t hese improvements are not 
proven, increase in pulmonary function42 and decrease risk of BPD are potential benefits for 
participant s enrolled in the study  who receive furosemide.  Conclusions drawn from this study 
will benefit infants receiving furosemide in the future through better understandi ng of dose 
response and c haracterization of the safety profile of these drugs.  
 
 ____________________________________________________________________________________________  
19 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
3 OBJECTIVES  
 
Primary:  Describe the safety of furosemide in premature infants at risk of BPD  
 
Secondary: Preliminary effectiveness and pharmacokinetics (PK) of furosemide.  
3.1 Study Outcome Measures 
3.1.1  Primary Outcome Measures  
Safety  as determined by [CONTACT_60235] s experienced by [CONTACT_3038].  
3.1.2  Secondary Outcome Measures 
[IP_ADDRESS]  Preliminary effectiveness: R isk of BPD  
The outcome measure is change in moderate -severe BPD or death risk from baseline. 
Moderate- severe BPD or death risk will be defined by [CONTACT_423734]. (https://neonatal.rti.org/index.cfm?fuseaction=BPDCalculator.start ).  
 
The BPD outcome estimator uses the following information to provide individual risk of BPD : 
1. Gestational age (weeks)  
2. Birth weight (g)  
3. Sex 
4. Maternal Race/Ethnicity  
5. Postnatal day 
6. Ventilation type (on the postnatal day of interest)  
7. FiO2 (%) (on the postnatal day of interest)  
 
Note: The BPD estimator provides an estimate of the risk of BPD (as defined by [CONTACT_4289]: none, mild, moderate, severe) or death by [CONTACT_423735]. The ris k of BPD is presented as a %. For this 
protocol, we will dichotomize the outcome as above (none- mild vs. moderate -severe- death).  
For example, a 25 week Hispanic female with birth weight of 689 g on postnatal day 14 on 
mechanical ventilation with a FiO
2 of 0.45 has risk of no BPD of 1.6%, mild 27.9%, moderate 
28.9%, severe 30.5%, and death 11%. Thus, none- mild risk is 29.5% and moderate -severe-
death risk is 70.5%.   
 
We will collect risk of BPD  or death as defined by [CONTACT_423736] 7, 14, [ADDRESS_535306] to the day  used to calculate the BPD 
estimator . The BPD estimator includes infants up to 28 postnatal days; for infants in this 
protocol older than that, we will use the 28 day estimates.  
[IP_ADDRESS]  Pharmacokinetics  
A population PK analysis will be performed. Using the final population PK model, empi[INVESTIGATOR_423708] (CL), volume of distribution (V), half life, and exposure metrics 
(e.g. AUC, maximum concentration) will be generated for each patient.  
 
3.1.3  Other safety and efficacy outcomes  
1. Death: All infants who died at or before 36 weeks PMA  will be included.  
 ____________________________________________________________________________________________  
20 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
2. BPD: We will define BPD as it was defined for the NICHD BPD estimator.  We will 
define BPD as a dichotomous (none- mild vs. moderate -severe) variable and as a 
categorical variable (none, mild, moderate, or severe) among survivors by [CONTACT_423737]20,21 to include infants transferred prior to 36 
weeks and the need for oxygen at 36 weeks PMA (or discharge, if sooner than 36 
weeks PMA).29 We will define BPD as follows:   
1. No BPD: receiving > 21% supplemental oxygen (O 2) for ≤ 28 days ) and not  at 36 
weeks  PMA  
2. Mild BPD : receiving  > 21%  O2 for ≥28 days  but not at 36 weeks  PMA  
3. Moderate BPD : receiving > 21% O 2 for ≥28 days  plus treatment with <30% O 2 
at 36 weeks  PMA  
4. Severe BPD : receiving > 21% O 2 for ≥28 days  plus ≥30% O 2 and/or positive 
pressure at 36 weeks  PMA  
5. Death or BPD : either 1 or 2  
6. Hearing loss: Hearing loss will be identified by [CONTACT_423738] ( e.g. BAER) prior to 
 discharge.  
7. Nephrocalcinosis/nephrolithiasis:  Nephrocalcinosis/nephrolithiasis will be 
determined by [CONTACT_423739].  Renal ultrasounds that are positive for nephrocalcinosis or 
nephrolithiasis will  be reviewed by [CONTACT_423740].  
 
 ____________________________________________________________________________________________  
21 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
4 STUDY DESIGN  
See Protocol Synopsis.  
 
This study will be conducted in accordance with current U.S. Food and Drug Administration 
regulations and guidelines, ( or, as applicable, international regulations and associated 
guidelines ), the International Conference on Harmonisation Guidelines on Good Clinical 
Practice (which incorporate the principles of the Declaration of Helsinki), as well as all other 
applicable national and local laws and regulations.  
 
 ____________________________________________________________________________________________  
22 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
5 STUDY P OPULATION  
5.1 Selection of the Study Population  
Premature  infants (inpatient in neonatal intensive care units) will be randomized in a dose 
escalating approach 3:1 (furosemide:placebo) into 3 Cohort s with escalating doses of 
furosemide.   There will be 40 randomized and dosed participants in each Cohort  for a total of up 
to 120 participants.  
5.2 Inclusion/Exclusion Criteria  
Inclusion Criteria  
1. Documented informed consent from legal guardian, prior to study procedures  
2. Receiving positive airway pressure (nasal continuous airway pressure, nasal intermittent 
positive pressure ventilation, or nasal cannula flow > 1LPM) or mechanical ventilation 
(high frequency or conventional)  at time of randomization 
3. < 29 weeks gestational age at birth  
4. 7-28 days postnatal age at t ime of randomization 
 
Exclusion Criteria  
1. Exposure to any diuretic ≤ 72 hours prior to randomization  
2. Previous enrollment and dosing in current study, “ Safety of Furosemide in Premature 
Infants at Risk of Bronchopulmonary Dysplasia”  
3. Hemodynamically signific ant patent ductus arteriosus, as determined by [CONTACT_093]  
4. Major congenital anomaly (e.g. congenital diaphragmatic hernia, congenital pulmonary adenomatoid malformation)  
5. Meconium aspi[INVESTIGATOR_1518]  
6. Known allergy to any diuretic  
7. Serum creatinine >1.7 mg/dl < 24 hours prior to  randomization 
8. BUN >50 mg/dl < 24 hours prior to randomization  
9. Na <125 mmol/L < 24 hours prior to randomization  
10. K ≤2.5 mmol/L < 24 hours prior to randomization  
11. Ca ≤ 6 mg/dL (or ionized calcium  ≤3.2 mg/dl) < [ADDRESS_535307] bilirubin >10 mg/dl < 24 hours prior to randomization*  
13. Any condition which would make the participant, in the opi[INVESTIGATOR_871], unsuitable for the study  
 
*If total bilirubin is measured without the differentiated (conjugated (direct) and 
unconjugated (indirect)) fractions and is ≤10mg/dl, this value can be accepted for 
determination of indirect bilirubin ≤10mg/dl.   
5.3 Treatment Assignment Procedures  
5.3.1  Additional Participants  
If a participant is randomized (see 5.3.2) and receives <  7 days of study drug, then additional 
participant s may be enrolled.  
 ____________________________________________________________________________________________  
23 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
5.3.2  Randomization Procedures 
Participants who satisfy all eligibility  criteria will be randomized 3:1 (furosemide: placebo ). All 
three Cohort s will use the same randomization scheme. The first 40 subjects will be enrolled in 
Cohort 1, and dose escalation via enrollment in other Cohorts will occur only after  safety criteria 
are satisfied (see section 8.5). Participants  randomized to placebo will receive the standard of 
care with regards to fluid imbalance; use of similar strategies for fluid and ventilator 
management will be part of the site selection criteria.  
 
The participant’s randomized treatment assignment will be obtained through the AdvantageEDC 
enrollment module. In the event that AdvantageEDC is not available at the time of 
randomization, a back -up system specified in the MOP  will be used.  
 Randomization will be stratified by [CONTACT_384] . If a participant is randomiz ed but does not receive 
study drug, that participant will not count towards total sample size and will be replaced by a 
new participant who, in turn, will be assigned a new identification number  and receive treatment 
corresponding to  the new identification number . The reason for not dosing the participant will be 
noted on the  CRF.  
 
 
5.3.3  Masking  Procedures  
Infants randomized to the placebo treatment group will receive the equivalent volume of 
dextrose 5% appropriate for IV use  or enteral use (if receiving enteral study drug) . The 
Pharmacy at each site will prepare and dispense the study drug into appropriate sized syringes  
in a masked  manner , staff a ssessing participant outcomes will be blinded to treatment.  
 
 
5.3.4  Reasons for Parti cipant Withdrawal  
The clinician may choose to suspend study drug dosing for up to 48 hours for any reason.    
 
 
The investigator will withdraw a participant from receiving further study interventions if:  
1. Any clinically significant adverse event (AE) is deemed by [CONTACT_458] [INVESTIGATOR_423709] .  The participant will continue to be 
followed for safety for [ADDRESS_535308] dose and complete all remaining follow up 
assessments unless consent has been wit hdrawn.  
2. Suspension of the study drug for >[ADDRESS_535309] is suspended for >[ADDRESS_535310] 
dose and complete all remaining follow up assessments unless consent has been 
withdrawn.  
4. Requested by t he NIH, FDA, PTN, or DMC.  
5. Participants’ parent or legal guardian may withdraw voluntarily from participation in the 
study at any time. Participants’ parent or legal guardian is not obligated to state the 
 ____________________________________________________________________________________________  
24 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535311] 
be documented by [CONTACT_328254]/ withdrawal section of the 
electronic case report form (CRF).  
 
6. Before discontinuing a participant from the investigational product, the local investigator must contact [CONTACT_423741]/or protocol PI /Chair  except in emergency 
situations . If the site cannot wait until the next business day, it will be considered an 
emergency situation. Participants who are prematurely discontinued from receiving study  
product  for any reason will be followed for 7 days for adverse event monitoring and 
complete all remaining study assessments  unless consent has been withdrawn.  
5.3.5  Termination of Study  
This study may be terminated at any time by  [CONTACT_8415], NIH, the Investigational New Drug 
Application ( IND) sponsor , or the Data Monitoring Committee (DMC ). 
 ____________________________________________________________________________________________  
25 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
6 STUDY PROCEDURES  
6.1 Summary o f Procedures  
 
Table 6-1: Schedule of s tudy  procedures  
 Screen / 
Baseline  Treatment  Follow -up  36 weeks 
PMA 
assessment  Final study 
assessment  
Time (Day)  [ADDRESS_535312]  
study dose  36 weeks  PMA  Discharge/ET/ 
or Transfer  
Informed consent  X     
Demographics  X     
Physical examination  X  X X  
Medical history  X     
Actual Weight  X  X X  
Respi[INVESTIGATOR_423710]  X X (Q WEEK)  X X X 
Laboratory evaluations  X X6 (2X WEEK)  X X  
Study drug administration   X    
Concomitant medications   X    
Adverse events  X4 X X   
Blood  sampling   X (AFTER DAY 
7)    
Hearing scr een     X 
Renal ultrasound   X5 X5 X5 X 
Discharge information3     X 
1 Refers to time point prior to start of study drug and may be the same calendar date as day 1   
2 While on study drug  
3 Transfer, discharge, or death  
4 AEs will be collected f ollowing initial study -specific procedure (e.g., screening blood draws, dosing ) 
[ADDRESS_535313] of care  
6.2 Screening  
Infants <  29 weeks GA at birth  will be screened for eligibility.  
6.3 Enrollment/Baseline  
Research staff will document informed consent from the parent/guardian for all participants who 
satisfy eligibility  criteria .  
 
 ____________________________________________________________________________________________  
26 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535314] : 
 
1. Participant demographics , including birth weight and gestational age at birth  
2. Medical history  
3. Physical examination, including weight  
4. Respi[INVESTIGATOR_423710] ( see 6.8)  
5. Laboratory evaluations  (see 6. 9) 
6. Adverse events following initial study -specific procedure (see 6.11)  
6.[ADDRESS_535315] day of study drug if early  withdrawal  of 
study therapy . 
 
The following information will be collected w hile the participant is on study : 
1. Weight , assessed every  7 (+/- 1) days throughout the treatment period  
2. Date, time, and route of each study drug dose will be recorded  
3. All concomitant medications  
4. Respi[INVESTIGATOR_423710] , weekly  (see 6. 8) 
5. Laboratory evaluations , at leas t 2x/week minimum  (see 6. 9). 
6. PK sampling (see 6. 10) 
7. Results of renal ultrasound if performed per SOC; specifically  
nephrocalcinosis/nephrolithiasis  
8. Adverse events  (see 6. 11) 
6.[ADDRESS_535316] study dose,  including in case s of early 
withdrawal  of study therapy .  
 
The following information will be reported at Day  7 (or day closest to Day  7, if > 1 assessment is 
available) :  
1. Physical examination, including weight  
2. Respi[INVESTIGATOR_423710] (see 6.8)  
3. Laboratory evaluations  (see 6.9)  
4. Results of renal ultrasound, if performed per SOC  
5. Adverse events  (all during the follow -up period)  (see 6.11)  
6.[ADDRESS_535317] to discharge date.   (Record latest 
results within week 36 if > 1 assessment is available) : 
1. Physical examination, including weight  
2. Respi[INVESTIGATOR_423710] (see 6.8)  
3. Laboratory evaluations (see 6.9)  
4. Results of renal ultrasound (if obtained  per SOC ) 
 ____________________________________________________________________________________________  
27 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
6.7 Final Study Assessment  
Final study assessment will occur at the time of discharge, early termination or transfer and the 
following information will be collected:   
1. Respi[INVESTIGATOR_423710] (see 6. 7) 
2. Results of h earing test  (e.g. BAER; must be performed if not done per SOC  after the 
treatment period) . If multiple tests are performed  per SOC throughout the study period,  
all results should be recorded in AdvantageEDC.   
3. Results o f renal ultrasound (must be performed if not done per SOC after the treatment 
period) .  If multiple tests are performed  per SOC throughout the study period, all results 
should be recorded in AdvantageEDC . 
4. Discharge information  
a. Home or t ransfer  
b. Died or alive  
c. Duration of hospi[INVESTIGATOR_059] 
6.8 Respi[INVESTIGATOR_423711],  on day 7, 14, 21, and 28 (+/- 1 day) of 
study drug administration, once during the follow -up period,  once at 36 weeks PMA , and once at 
discharge:  
1. Maximum F iO2 (defined as the m aximum FiO 2 on day of assessment, unless it is known 
to be a temporary (<2 hour) increase in FiO 2) 
2. Ventilation type:  
a. High frequency ventilator  
b. Conventional mechanical ventilator  
c. NCPAP (or equivalent, see inclusion criteria in protocol synopsis table)  
d. Cannula/Hood 
e. None (room air with no support)  
6.[ADDRESS_535318] be conducted (if not obtained per  SOC) prior to 
randomization (within 24 hours of randomization) , and at least 2 times per week  (at least 4 2 
hours apart) .  For cohort [ADDRESS_535319] bilirubin*   
2. Sodium  
3. Potassium  
4. Bicarbonate  
5. BUN  
6. Creatinine 
7. Calcium  and/or ionized calcium  
*If a total bilirubin value is measured without the differentiated ( conjugated (direct) and unconjugated 
(indirect))  fractions and is ≤ 10mg/dl, this value can be reported instead of indirect bilirubin  
 
 ____________________________________________________________________________________________  
28 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535320] be entered into the EDC system.  
SOC laboratory evaluations: We will also record val ues for  platelets, phosphorus, chlo ride, 
alkaline phosphatase, and caffeine levels from [ADDRESS_535321] dose of study drug if reported  per SOC.   The values will also be captured at 36 
weeks PMA if reported per SOC.  
6.10 PK Sampling  
Table 6 -2 below provides the optimal sampling collection windows. Blood samples will be 
collected after any dose following completion of 7 days (168 hours) of study drug administration. 
Every effort should be made to collect plasma samples within the below windows; however, 
samples obtained outside of the sampling windows will not be considered protocol deviations. 
Sample collection windows are relative to the end of the infusion; all samples should be 
collected after the flush. Blood samples should not be drawn during i nfusions or during the flush. 
Elimination samples will only be obtained around the last dose of study drug.  
 
Table 6-2: Optimal sampling collection windows (time in relation to end of infusion)  
 
Dosing interval (hour s) 
 
Sample #  
6 Hour   
24 Hour  
1 within 30 min  within 30 min  
2 2-4 hours  2-4 hours  
3 Within 30 min prior to next dose  6-8 hours  
4 12-18 hours (elimination)  12-16 hours  
5 N/A 20-22 hours  
6 N/A Within 30 min prior to next dose  
7 N/A 48-72 hours  (elimination)  
 
6.10.1  Minimizing Blood Loss  
Plasma samples will be collected in 200 μL blood aliquots. To minimize the amount of blood 
sampling, a limited sampling scheme will be employed such that no more than 7 timed PK 
samples (1.4 mL of blood) are obtained from each participant for analysis.  Participants in all 
treatment groups (including placebo) will have samples collected. Infants assigned to the 
placebo treatment group will have biomarkers of bronchopulmonary dysplasia measured in a 
central laboratory (details in MOP; biomarkers may include:  IL-1, IL-6, IL-8, TNF -α, and 
RANTES)  instead of PK levels . 
 ____________________________________________________________________________________________  
29 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
6.10.2  Specimen Preparation, Handling, and Shippi[INVESTIGATOR_423712].  
6.11 Adverse Event  
AEs will be collected following initial study -specific procedure (e.g., screening blood draws,  drug 
administration) , through  [ADDRESS_535322] study dose. See section 8 for safety information.  
 ____________________________________________________________________________________________  
30 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535323] DESCRI PTION  
7.1 Dosage and Study Drug Information  
Table 7-1: Dosing  
Table. N and dosing scheme  
  N Furosemide  
(IV) or Furosemide  
(enteral)  N Cohort N  
Cohort 1  Placebo  10 1 mg/kg q 24 
hours  or 2 mg/kg q 24 
hours  30 40 
Cohort 2*  Placebo  10 1 mg/kg q 6 
hours  or 2 mg/kg q 6 
hours  30 40 
Cohort 3*  Placebo  10 2 mg/kg q 6 
hours  or 4 mg/kg q 6 
hours  30 40 
* See dose escalat ion, below, for Cohorts 2 and 3  
 
Dosing escalation for participants in Cohort 2 and Cohort 3:  Participants enrolled in Cohort  
2 and Cohort  3 will initially start at 1 mg/kg q 24 hours of study drug and will increase to the 
assigned target in “every other day” increments.  For example, infants assigned to Cohort 3 who 
are receiving IV dosing will start at 1 mg/kg q 24, then 1 mg/kg q 12, then 1 mg/kg q 6, and then 
2 mg/kg q 6, in this example the assigned target dose would be achieved on t reatment day 7.  
NOTE: Dosing will increase as long as the BUN ≤ 50 mg/dL, the creatinine is ≤ 1.7 mg/dL, the Na is >  125 mmol/L, and the K is > 2.5 mmol/L, Ca >6 mg/dL (or ionized Ca > .8 mmol/L)  on 
surveillance chemistries  obtained within 48 hours prior to dose escalation. An infant will meet 
respi[INVESTIGATOR_423713] (nasal cannula or positive pressure from any device)  for at least [ADDRESS_535324] occur within 24 hours of an infant meeting all criteria  (respi[INVESTIGATOR_423714]) .  If es calation does not occur wi thin this timeframe,  then a protocol deviation 
must  be recorded.   
 
Weight:   
• Actual weight will be recorded at baseline, once during safety follow -up, and at 36 weeks 
PMA.  
• Dosing weight is the weight utilized to determine dosing (which may be different from 
actual weight), and will be recorded for each study dose. Dosing should be reassessed 
for adjustment according to any dosing weight changes determined every 7 (+/ - 1) day s 
throughout the treatment period. There is no protocol requirement to modify dose based 
solely  on actual weight. Dose may or may not be adjusted based on the weight.  
 
Open label diuretics:  Administration of other diuretics during the study period (day 1- 28) will be 
considered a protocol deviation because administration of no diuretics is considered part of 
standard of care at some centers. Clinicians may choose to administer diuretics after day 28 at 
their discretion.  
 
 ____________________________________________________________________________________________  
31 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
Na/K supplementation  Na and K supplementation is permitted at the discretion of the clinical 
team.  
 
Intravenous (IV) versus enteral dosing:  If the participant does not have an IV or if the clinical 
team elects  to use enteral dosing, then the dose of study drug will be twice that of the IV dosing 
(from the product label). Placebo will be administered either enterally or IV as well.  
 
7.[ADDRESS_535325] will be “off the shelf” as provided by [CONTACT_779]’s pharmacy. Detailed 
information will be part of the MOP.  
 
7.3 Preparation and Administration of Study Intervention/Investigational Product  
The p harmacy at each site will prepare and distribute the study drug in a masked manner to the 
NICU/PI[INVESTIGATOR_423715]. Intravenous doses of study drug 
will be ad ministered within15 minutes.  Enteral doses will be administered w ith feedings.  The 
enteral formulation, if used, will be administered enterally either by [CONTACT_1966], orogastric, 
nasogastric, gastrostomy tube, or other enteral tubes. For enteral administration in infants 
receiving  bolus feedings, mixing and timing of adminis tration should follow the institutional 
policy.  If  there is  no specific institutional polic y, study drug will be mixed in [ADDRESS_535326]  occur within:  
• +/- 3 hours of the scheduled time of q24h dosing,  
• +/- 2 hours of the scheduled time for q12h dosing,  
• +/- [ADDRESS_535327] Storage and Stability  
Detailed information will be part of the MOP.  
7.5 Concomitant Medications/Treatm ents 
All drug s and/or treatments, other than additional diuretics, are permitted while on study. Use of 
other or additional diuretics is considered a protocol deviation. All concomitant medications , 
including intravenous potassium boluses  or enteral electr olyte supplements , and treatments 
(including other diuretics) will be reported during the study drug administration period. We will 
 ____________________________________________________________________________________________  
32 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535328] of 
care furosemide,  are administered during the study drug administration period will be  
considered a protocol deviation.  
 ____________________________________________________________________________________________  
33 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535329] study dose and it  will be assessed by [CONTACT_423742]. A safety monitoring committee (DMC) will be convened by [CONTACT_423743] 2 and 3.  
8.1.1  Adverse Event  
An adverse event  (AE) is any untoward medical occurrence in humans, whether or not 
considered drug -related,  which occurs during the conduct of a clinical trial. (Any  change in 
clinical status , routine labs, x -rays, physical examinations, etc. ), that is considered clinically 
significant by [CONTACT_65227]. 
 
Suspected adverse reaction  is any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. A reasonable possibility implies that there is evidence 
that the drug caused the event.   
 
Adverse reaction is any adverse event caused by [CONTACT_33641].   
 
Serious adverse event  or serious suspected adverse reaction  or serious adverse reaction 
as determined by [CONTACT_941] i nvestigator or the sponsor is any event that results in any of the following 
outcomes:  
1. Death 
2. Life-threatening AE ( “life-threatening”  means that the study participant was, in the 
opi[INVESTIGATOR_26335], at immediate risk of death from the reaction as it 
occurred and r equired immediate intervention)  
3. Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
4. Inpatient hospi[INVESTIGATOR_1081] 
5. Important medical event that may not result in one of the above outcomes, but may jeopardize the health of the study participant or require medical or surgical intervention 
to prevent one of the outcomes listed in the above definition of serious event  
8.1.[ADDRESS_535330] pre- existing medical conditions an d may be currently 
hospi[INVESTIGATOR_057], those pre- existing conditions will not be considered as adverse events. New 
events that occur or pre -existing conditions that worsen in terms of  frequency or intensity will be 
reported as adverse events.   
 
 ____________________________________________________________________________________________  
34 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
All reportable ev ents as defined above, determined to be an AE based on physical examination, 
laboratory findings , or other means , will be reported in the electronic case report form (e- CRF). 
The investigator will provide the date of onset and resolution, intensity, frequency, action(s) 
taken, changes in study drug dosing, relationship to study drug, and outcome.  
8.1.4  Follow -up of Adverse Events 
All events (study -related or not) must be followed until resolution, or  if ongoing at the time of last 
safety contact , will be fo llowed up to adequately evaluate the participant’s safety or until the 
event stabilizes . All serious suspec ted adverse reactions and serious adverse reactions will be 
followed until resolution or unt il the patient is medically stable. All other events that canno t be 
resolved by 30 days after the safety monitoring period will be cons idered resolved by 
[CONTACT_423744] (EDC ) system as such. Any event 
beginning more than [ADDRESS_535331] dose of study drug will not be captured.   
8.1.5  Guidelines for Assessing Intensity of an Adverse Event  
The investigator should use the following definitions when assessing i ntensity of an a dverse 
event:  
1. MILD:  Participant is aware of symptoms  or has minor findings but tolerates them well , 
and no or minimal intervention required  
2. MODERATE : Participant experiences enough symptoms or findings to require 
intervention  
3. SEVERE:  Participant experiences symptoms or findings that require significant 
intervention 
8.1.6  Guidelines for Determining Causality  
The investigator will use the following question when assessing causality of an adverse event to 
study drug , where an affirmative answer designates the event as a suspected adverse reaction:  
Is there a reasonable possibility that the drug caused the event? ‘‘Reasonable possibility’’ 
means that there is evidence to suggest a causal relationship between the drug and the adverse 
event.  
8.1.[ADDRESS_535332] be followed by [CONTACT_423745]. Any participant who experiences an AE m ay be 
withdrawn at any time from the study at the discretion of the investigator. The AE(s) should be 
noted on the appropriate CRFs , and the participant’s progress should be followed until the AE is 
resolved or considered stable. The medical monitor or project manager must be notified. If the 
AE may relate to overdose of study treatment, the package insert should be consulted for 
details of any specific actions to be taken.  
 ____________________________________________________________________________________________  
35 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535333] communication with the medical 
monitor . Results of hearing  tests (hearing loss / impairment ) and renal ultrasound 
(nephrocalcinosis / nephrolithiasis ) are considered adverse events of interest and will be 
captured on the SPE (Special Testing) form and will not be captured on the AE (A dverse 
Events ) form  in the E DC system .  
8.[ADDRESS_535334] also 
submit safety reports locally as required by [CONTACT_11577] . 
8.3 Regulatory Reporting  
Any event that requires expedited reporting based on federal regulations will be forwarded to 
the IND sponsor. The IND sponsor or its in -country representative will submit expedited safety 
reports ( e.g. IND safety reports) to the regulatory agencies as necessary, and will inform the 
investigators of such regulatory reports. Site investigators must submit safety reports as 
required by [CONTACT_11577]. Documentation of the submission and receipt by [CONTACT_423746].  
 
All serious events  irrespective of their  designation as “related”  or “not related” to study 
product(s) will be reported to the FDA at least annually in a summary format.  
 
8.[ADDRESS_535335]. The medical monitor will also indicate whether 
he/she concurs with the details of the report provided by [CONTACT_1704]. If no SAEs 
prompt review at an earlier time point, the DMC will review  AEs and SAEs at the regularly 
scheduled meeting.  Additionally, DMC will periodically review interim safety analyses (see 
Section 10.3).  The DMC will convene and make recommendations on termination of the study 
based on review of safety reports and halting rules. The safety data will be compi[INVESTIGATOR_328227]. 
Based on the r ecommendations of the DMC, and NIH , the IND sponsor will make a decision to 
terminate or continue the study.  
 
8.5 Dose Escalation and Halting Criteria: Safety Concerns 
The trial will be halted (paused) for a safety review by  [CONTACT_328269] 4 or more S erious 
Adverse Reactions within a given cohort  (1, 2, or 3). If there are <4 S erious Adverse Reactions 
 ____________________________________________________________________________________________  
36 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535336]  dose cohort  will begin immediately 
after the 40th (or 80th) subject i s enrolled and the following criteria have been met:  
 
Table 8 -5 – Rules for advancing to next highest dose cohort  
Number of S erious Adverse 
Reaction s % total evaluable safety days (days of drug dosing + 7 days of safety 
follow -up for all 40 participants ) completed from lower dose cohort  
3 100% 
2 95% 
1 80% 
 0  70% 
If a 4th Serious Adverse Reaction occurs in the lower dose cohort after enrollment begins in 
higher dose cohort, enrollment will be halted for safety review but current subject dosing will 
continue pending DMC review. If there are 4 or more S erious Adverse Reactions, then the DMC 
may choose to be unmasked to treatment assignment.  
 
 
 
 ____________________________________________________________________________________________  
37 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535337] protection, study procedures, 
laboratory procedures, study intervention administration, and data collection processes are of 
high quality and meet sponsor, GCP/ICH, and regulatory guidelines, and that the study is 
conducted in accordance with the protocol and DCRI sponsor standard operating procedures.  
The IND sponsor, or as detailed in the Transfer of Re gulatory Obligations (TORO),  NIH, FDA, 
or its designee will conduct site- monitoring visits as detailed in the monitoring plan or in the 
manual of p rocedur es.  
 Site visits will be made at standard intervals as defined by [CONTACT_328270].  Monitoring visits will include, but are not 
limited to, review of regulatory files, accountability records, CRFs , informed consent forms, 
medical and laboratory reports, and protocol compliance.  Study monitors will meet with 
investigators to discuss any pr oblems and actions to be taken and document visit findings and 
discussions.  
 ____________________________________________________________________________________________  
38 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
10 STATISTICAL CONSIDER ATIONS  
10.1 Study Endpoints  
Primary safety endpoints are the incidence of AEs and SAEs . Secondary endpoints include 
BPD risk, BPD incidence, death rate, rate of deat h or BPD, incidence of 
nephrocalcinosis/nephrolithiasis, incidence of hearing loss, and PK parameters.  
10.2 Sample Size Considerations  
The sample size of 30 in each dose group is sufficient to estimate AE or SAE incidence with 
sufficient precision. Table 9- 1 provides widths for 95% Wilson  confidence intervals in the dose 
groups of size 30 and the total furosemide treatment cohort  of 90 wi th different incidence rates. 
An event with an incidence rate of 0.05 has a 79% chance of being observed at least once in a 
dose group and a 99% chance of being observed at least once in the total furosemide cohort.  
 
Table 9 -1. Widths for 95% Wilson confid ence intervals.  
 
N=30  N=[ADDRESS_535338] one interpretable PK sample will be included in 
the PK analysis.  
10.3 Interim Safety Analysis  
A masked  interim safety analysi s will be performed after completion of  the safety follow up 
period of Cohort 1  participants , and again a fter completion of the safety follow up period of  
Cohort 2 participants to include data entered up to the cutoff time point . Enrollment will not be 
halted during the analyses.   Halting may occur if analysis shows a positive finding.  The number 
and percent of AEs and SAEs within each dose group will be summarized overall as well as  by 
[CONTACT_271683] (MedDRA) system organ class and preferred 
term. Laboratory data will be tabulated by [CONTACT_144169]. Summary statistics for chang es from 
baseline will be presented.  
10.[ADDRESS_535339] error, minimum and maximum will be presented by [CONTACT_328273] 
(such  as age, weight, etc .). Other descriptive statistics such as counts, proportions, and/or 
percentages will be presented by [CONTACT_328274] (such as race, sex, etc.) 
 
 ____________________________________________________________________________________________  
39 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
Demographic and baseline characteristics  
The number of participants completed and discontinued early from study and the reasons for 
the discontinuation will be summarized. Demographic and baseline characteristics will also be 
summarized. Variables include race, age, sex, and selected clinical var iables recorded prior to 
initiation of study drug. Study drug administration will be summarized in terms of number of days 
of dosing and reasons for final discontinuation of study drug.  
 
 
Effectiveness analysis 
We will use multivariable analyses (multinom ial, logistic or linear regression, with interactions, 
as appropriate) to explore the relationship between the maximum and total dose of furosemide and change in risk of BPD (none- mild vs. moderate- severe- death), death, death or BPD, 
hearing loss, and neph rolithiasis/nephrocalcinosis.  
 
PK analysis plan 
PK parameters will be estimated by [CONTACT_423747] -linear mixed effects 
modeling in NONMEM. The influence of covariates on PK parameters will be explored.  
 
Biomarkers  
We will relate the concentration of biomarkers (see 6.10) to the development of and severity of 
BPD.  
 
Safety  
The number  and percent  of AEs and SAEs within each dose group will be summarized overall 
and by  [CONTACT_271683] (MedDRA) system organ class and 
preferred term. Severity of laboratory values will be assigned according to predetermined definitions (Appendix A). Prior and concomitant medications will be summarized by [CONTACT_423748] (WHO) drug class. Laboratory data will be tabulated by [CONTACT_144169] . 
Summary stati stics for changes from baseline will be presented.  Incidences of hearing loss and 
nephrolithiasis/nephrocalcinosis will be compared between dose groups using appropriate 
statistical hypothesis tests.  
 
 ____________________________________________________________________________________________  
40 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535340] by [CONTACT_3486], their staff, and 
the sponsor(s) and their agents.  This confidentiality is extended to cover testing of biological 
samples and genetic tests , in addition to the clinical information relating to participating 
participant s. 
 
The study protocol, documentation, data , and all other information generated will be held in 
strict confidence.  No information concerning the study or the data will be releas ed to any 
unauthorized third party without prior written approval of the sponsor.  
 
The study monitor or other authorized representatives of the sponsor may inspect all documents 
and records required to be maintained by [CONTACT_093]. This documentation includes, but is 
not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. Clinical study sites will permit access to such records.  
 
Copi[INVESTIGATOR_423716] (nephrocalcinosis) or kidney stones ( nephrolithiasis) will be submitted in a secure 
manner to the Data Coordinating Center. The Data Coordinating Center will remove any PHI 
that identifies the participant fr om the images before they are sent to a study radiology specialist 
for independent review.  The study radiologist’s assessment of the ultrasounds are for study 
purposes only, and individual results will not be reported back to investigators . 
 
The principal investigator [INVESTIGATOR_423717] p rotected health information 
(PHI) obtained during this research study complies with the Federal Privacy Regulation. In the 
U.S., the Health Insurance and Portability and Accountability (HIPAA) Privac y Rule applies. The 
rule provides U.S. federal protection for the privacy of protected health information sent to or 
collected in the U.S. for the purposes of this research by [CONTACT_423749] i dentifiable health information of participants 
participating in clinical trials. “Authorization” is required from each research participant (i.e., 
specific permission granted by [CONTACT_60682] a covered entity for the use or disclosure of an 
individual’s  protected health information). A valid authorization must meet the implementation 
specifications under the applicable Federal Privacy Regulations . The relevant privacy 
authorization will be combined in the informed consent document (approved by [CONTACT_1201]).   
 ____________________________________________________________________________________________  
41 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
12 INFORMED CONSENT PRO CESS  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continuing throughout the individual’s study participation.  Extensive discussion of 
risks and possible benefits of  participation in this study will be provided to the participant s and 
their families.  Consent forms describing in detail the study procedures and risks are given to the 
participant ’s legal guardian , and written documentation of informed consent is required prior to 
enrolling in the study.  Consent forms will be IRB -approved,  and the participant ’s legal guardian 
will be asked to read and review the document.  Upon reviewing the document, the investigato r 
will explain the research study to the participant ’s legal guardian  and answer any questions that 
may arise.  The participant/participant ’s legal guardian will sign the informed consent document  
prior to the conduct of any study procedures . The participant ’s legal guardian should have the 
opportunity to think about the study prior to agreeing to participate.  The participant ’s legal 
guardian may withdraw consent at any time throughout the course of the study.  A copy of the 
informed consent document will be given to the participant s for their records.  The rights and 
welfare of the participant s will be protected by [CONTACT_423750]. For non- English speakers, a fully translated consent or an oral presentation accompanied 
by a short form may be used to obtain informed consent. The fully translated consent and the 
short form must be approved by [CONTACT_423751].  
 
The IND sponsor, or designee will provide the investigator, in writing, any new information that 
bears significantly on the participants' risk to receive the investigational product. This new 
information will be communicated by [CONTACT_271688]' legal guardians who 
consent to participate in the trial in accordance with IRB requirements. The informed consent 
document will be updated, and participants’ legal guardians will be re- consented, if necessary.  
 
Site staff may employ IRB -approved recruitment efforts prior to the participant’s legal guardian 
consenting; however, before any protocol -specific procedures are performed to determine 
protocol eligibility, informed consent must be obtained and properly executed.  
 
By [CONTACT_423752], the participant’s legal guardian agrees that the participant 
will complete all evaluations required by [CONTACT_20767], unless the participant’s legal guardian withdraws the participant voluntarily or the participant is withdrawn from the trial for any reason.  
 ____________________________________________________________________________________________  
42 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
13 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
An electronic case report form (eCRF) will be used to record participation data. The e CRF will 
be used for the recording of all historical  participant information and study data as specified by 
[CONTACT_3181]. The eCRF must be completed by [CONTACT_222344].  
 
According to ICH E6, source data are defined as all information in original records and certified 
copi[INVESTIGATOR_34504],  observations, or other activities in a clinical trial 
necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copi[INVESTIGATOR_014]). Source documents are defined as original 
documents, data, and records (e.g., hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, 
memoranda, participant s’ diaries or evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, copi[INVESTIGATOR_423718], microfiches, photographic negatives, microfilm or magnetic 
media, x -rays, participant  files, and records kept at the pharmacy, at the laboratories, and at 
medico- technical departments involved in the clinical  trial).  
 It will be the responsibility of the investigator(s) to ensure that the regulatory binder at the site is 
maintained. The study file will contain, but will not be limited to:  
• Current package inserts, and all previous versions  
• Final study protocol  
• Protocol amendments (if applicable)  
• Manual of Procedures  
• Informed consent form (blank)  
• Signed informed consent form  
• Revised informed consent forms and/or all addenda (blank)  
• IRB registration  or other documentation of IRB compliance with FDA regulations  
• Documentation of IRB approval of protocol, consent form, any protocol amendments, 
and any  consent form revisions  
• Annual IRB updates and approvals  
• All correspondence between the investigator and IRB  
 
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with ICH E6, Section 4.9,  and regulatory and institutional requirements for the 
protection of confidentiality of participant s. Each site will permit authorized representatives of 
the sponsor, its designees , and appropriate regulatory agencies to examine (and , when required 
by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance reviews, audits, 
and evaluation of the study safety and progress.  These representatives will be permitted access 
to all source data, which include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, pharmacy dispensing records, recorded data from 
automated instruments, copi[INVESTIGATOR_423719] v erification as being accurate and 
complete, microfiches, photographic negatives, microfilm or magnetic media, x -rays, and 
participant  files and records kept at the pharmacy, at the laboratories, and medico- technical 
departments involved in the clinical tri al. Case report  forms will be derived from the eCRFs and 
provided by [CONTACT_36909] (DCC).  
 ____________________________________________________________________________________________  
43 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535341] access to all trial -related sites, source 
data/documents, case re port forms , and reports for the purpose of monitoring and auditing by 
[CONTACT_456], and inspection by [CONTACT_3482]. The p rincipal investigator will 
ensure that all study personnel are appropriately trained and applicable documentations are 
maintained on site.  
 
DCC- designated clinical  monitors will verify that the clinical trial is conducted and data are 
generated, documented (recorded), and reported in compliance with the protocol, Good Clinical 
Practice, and the applicable regulatory re quirements. Clinical monitoring reports will be 
submitted to the PI, PTN, and NI H/NICHD.  
 
The DCC will implement quality control procedures beginning with the data entry system and generate data quality control checks that will be run on the database. Any  missing data or data 
anomalies will be communicated to the site(s) for prompt clarification and resolution.  
 ____________________________________________________________________________________________  
44 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
15 ETHICS/PROTECTION OF  HUMAN PARTICIPANTS  
15.[ADDRESS_535342]  
The investigator will ensure that the study will be conducted in accordance with the prot ocol, the 
ethical principles of Good Clinical Practice (ICH E6) that have their origin in the D eclaration of 
Helsinki, and all applicable national and local regulations. The investigator will ensure that the 
study is conducted in accordance with the provis ions as stated and will comply with the 
prevailing local laws and customs.  
15.[ADDRESS_535343] 
Prior to enrollment of participants into this trial, the protocol, the informed consent form, and any 
materials or advertisements presented to participants will be reviewed and approved by [CONTACT_3809].  
 The responsible official for the IRB will si gn the IRB letter of approval of the protocol prior to the 
start of this trial , and a copy will be provided to the DCC.  Notification of the IRB's composition 
and the institution’ s federal -wide assurance number  (if applicable)  will be provided to the DCC.  
 
If amendments t o the protocol were required, the amendments will be written by [CONTACT_423753].  
15.3 Informed Consent  
The investigator will choose participant s in accordance with the eligibility criteria detailed 
previously. The investigator will not exercise selectivity so that bias is prevented.  In this study, 
participant ’s parent/legal guardian will sign  an informed consent for study participation.   
All legal guardians must sign an informed consent form that complies with the federal regulatory 
and privacy requirements before entering the trial. A consent form that complies with the federal 
requirements and a separate authorization form that complies with federal privacy regulations 
for the use and disclosure of the participant’s protected health information may be used instead, 
per institutional standard operating procedures . 
 
For details regarding the i nformed consent process, see Section 12.  
 
15.[ADDRESS_535344] by [CONTACT_3486], their staff, the 
sponsor(s), and their agents. This confidentiality extends to genetic and biological sample tests, 
in addition to the clinical information relating to participating participant s. 
 
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence.  No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the sponsor.  
 
The study monitor or other authorized representatives of the sponsor may inspect all documents 
and records required to be maintained by [CONTACT_093].  This documentation includes, but is 
 ____________________________________________________________________________________________  
45 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the 
participant s in this study.  Clinical study sites will permit access to such records.  
15.[ADDRESS_535345] be followed through resolution.  
 ____________________________________________________________________________________________  
46 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535346] this study in accordance with U.S. Federal Regulation 
21 CFR 312.60 -69 as specified on the signed form FDA 1572, applicable local laws, and the 
International Conference on Harmoni sation : Good Clinical Practice: Consolidation Guideline. 
The investigator is responsible for informing the IRB of any safety issues related to the study 
and the study drug , including reports of serious adverse events, if required, and all expedited 
safety reports.  
 
The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported.   
 Case report form s will be derived fro m the eCRFs and provided by [CONTACT_423754].  All source documents should 
be completed in a neat, legible manner to ensure accurate interpretation of data.  Permanent ink 
is required  to ensure clarity of reproduced copi[INVESTIGATOR_014].  When making a change or correction, the 
original entry should be crossed out with a single line, and the change should be initialed and 
dated.  Do not erase, overwrite, or use correction fluid or tape on the original .  
 
Data reported in the eCRF should be consistent with the case report form /source documents , or 
the discrepancies should be documented.  The sponsor and/or its designee will provide 
guidance to investigators on making corrections to the case report form s and eCRFs.  
16.[ADDRESS_535347] maint ain 
complete and accurate documentation for the study.  
 The DCC for this study will be responsible for data management, quality review, analysis, and 
reporting of the study data.  
16.2 Data Capture Methods  
Clinical data (including AEs and concomitant medications) will be entered into a [ADDRESS_535348] protection and internal quality checks, such as automatic range chec ks, to identify 
data that appear inconsistent, incomplete, or inaccurate.  Clinical data will be entered directly 
from the case report form s/source documents . 
16.3 Timing/Reports  
The DMC will convene and make recommendations on study continuation based on the sa fety 
data collected periodically .  
 
 ____________________________________________________________________________________________  
47 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # [ADDRESS_535349]  10 years after the end of the study or per 
local/state regulations or until participant s reach 21 years,  or applicable Federal laws,  whichever 
is longer . No study records will be destroyed without prior authorization f rom the sponsor.  
16.5 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or  manual of 
procedures requirements.  The noncompliance may be on the part of the participant , the 
investigator, or the study site staff.  As a result of deviations, corrective actions are to be 
developed by [CONTACT_3483].  
 
These practices are consistent with Good Clinical Practice:  
4.5. Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.[ADDRESS_535350] be promptly reported to the sponsor , 
via the DCC’s  Internet Data Entry System ( IDES ). 
 
All deviations from the protocol must be addressed in study case report form s. A completed 
copy of the p rotocol deviation form must be maintained in the regulatory file. Protocol deviations 
must be submitted to the local IRB/IEC per their guidelines.  The site PI/study staff is  responsible 
for knowing and adhering to their IRB requirements.  
16.6 Participant Privacy/Authorization  
The principal investigator [INVESTIGATOR_271656] a research study complies with the HIPAA Privacy Rule. The r ule provides U.S. 
federal protection for the pr ivacy of protected health information by [CONTACT_423755]. Authorization is required from each research participant (i.e., 
specific permission granted by [CONTACT_60682] a covered entity for the use or disclosure of an individual’s protected health information) . A valid authorization must meet the implementation 
specifications under the HIPAA Privacy Rule. Authorization will be combined in the i nformed 
consent document (approved by [CONTACT_1201]).  
 ____________________________________________________________________________________________  
48 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
17 PUBLICATION POLICY  
Following completion of the study, the investigator may publish the results of this research in a 
scientific journal  under the oversight of the Publication Committee of the Pediatric  Trails 
Network (PTN).  . The PTN Publication Committee comprises representatives of the n etwork 
cores, thought -leaders, DCC,  and PTN  and is responsible for generation and coordination of the 
publications that report scientific findings of the n etwork.  All public presentations (abstracts, 
manuscripts, slides and text of oral or other presentations, and text of any transmission through any electronic media) by [CONTACT_81597], participating institutions, DCC , and PTN that 
use PTN  data, are intended to represent the PTN, or are supported by [CONTACT_423756] c harter.  
 
The Publication Committee guarantees that the study results are presented by [CONTACT_271695], implementation, data synthesis/analysis , 
and interpretation.  The committee goals are to en sure that any confidential or proprietary 
information is protected, and that all appropriate statistical analyses have been included.   
 
The PTN Publication Committee will adhere to the trials  registration policy adopted by [CONTACT_19483] (ICMJE) member journal . This policy 
requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov , 
which is sponsored by [CONTACT_1055]. Other biomedical journals are 
considering adopting similar policies.  It is the responsibility of the IND holder to register this trial 
in an acceptable registry.   
 
The ICMJE defines a clinical trial as any research project that prospectively assigns human 
participant s to intervention or comparison groups to study the cause -and-effect relationship 
between a medical intervention and a health outcome.  Studies designed for other purposes, 
such as to study pharmacokinetics or major toxicity (e. g., phase I trials ), would be exempt from 
this policy.  
 
All investigators funded by [CONTACT_271696]’s PubMed Central an electronic version of their final, peer -reviewed 
manuscripts upon acceptance for public ation, to be made publicly available no later than [ADDRESS_535351] be 
accessible to the public on PubMed Central no later than 12 months after publication.   
 
Refer to:  
http://publicaccess.nih.gov/  and http://grants.nih.gov/grants/guide/notice -files/NOT -OD-08-
033.html  
 
 
 
   
 ____________________________________________________________________________________________  
49 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
18 APPENDIX A: LABORATORY VALUES 
Laboratory values  Adverse event  Serious adverse event  
Serum electrolytes  
Hypernatremia (Sodium ) 150–159 mmol/L  > 159 mmol/L  
Hyponatremia (Sodium ) 120–124 mmol/L  <120 mmol/L  
Hyperchloremia(Chloride)  110-120 mmol/L  > 120 mmol/L  
Hypochloremia(Chloride)  80-90 mmol/L  < 80 mmol/L  
Hyperkalemia (Potassium ) 7.0–7.9 mmol/L  >7.9 mmol/L  
Hypokalemia (Potassium ) 2.0–2.5 mmol/L  <2.0 mmol/L  
High Bicarbonate levels 
(Bicarbonate)  30–45 mmol/L  > 45 mmol/L  
Low Bicarbonate 
levels(Bicarbonate)  12–14 mmol/L < 14 mmol/L 
Hypercalcemia (iCa)  1.3–1.6 mmol/L  >1.6 mmol/L  
Hypocalcemia (iCa)  0.7–1.05 mmol/L  < 0.7 mmol/L  
Hypermagnesemia (Magnesium)  3.0-6.0 mg/dL  > 6.0 mg/dL  
Hypomagnesemia (Magnesium)  1.0-1.5 mg/dL  < 1.0 mg/dL  
Hypophosphatemia (Phosphorus)  
Hyperphosphatemia (Phosphorus)  1.0-3.0 mg/dL  
10.5-12.5 mg/dL  <1.0 mg/dL  
>12.5 mg/dL  
Hyperbilirubinemia (Bilirubin)  20-30 mg/dL  >30 mg/dL  
Renal dysfunction (i.e. azotemia)  
Elevated BUN  60–100mg/dL  > 100 mg/dL  
Elevated creatinine  1.5–2.5 mg/dL  > 2.5 mg/dL  
Gastrointestinal  
Elevated alkaline phosphatase  1000 –1400 U/L  >1400 U/L  
Hematology  
Thrombocytosis (Platelets ) 450–1000 × 10 ⁹/L >100010 × 10 ⁹/L 
Thrombocytopenia (Platelets ) 50–100 × 10 ⁹/L <50 × 10 ⁹/L 
 
 ____________________________________________________________________________________________  
50 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
19 LITERATURE REFERENCE S 
 
1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. Jun 
2001;163(7):1723 -1729.  
2. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health 
consensus definition of bronchopulmonary dysplasia. Pediatrics. Dec 2005;116(6):1353 -
1360.  
3. Coalson JJ, Winter V, deLemos RA. Decreased alveolarization in baboon sur vivors with 
bronchopulmonary dysplasia. American Journal of Respi[INVESTIGATOR_696] & Critical Care Medicine. 
1995;152(2):640 -646. 
4. Jobe AJ. The new BPD: an arrest of lung development. Pediatric Research. 
1999;46(6):[ADDRESS_535352] WH, Rosan RC, Porter DY. Pulm onary Disease Following Respi[INVESTIGATOR_423720] -Membrane Disease. New England Journal of Medicine. 1967;276(7):357- 368. 
6. Bancalari E. Barotrauma to the lung. In: A M, ed. Advances in Perinatal Medicine. New 
York: Plenum; 1982.  
7. Bancalari E, Gerha rdt T. Bronchopulmonary dysplasia. Pediatric clinics of North 
America. Feb 1986;33(1):1- 23. 
8. Stoelhorst GM, Rijken M, Martens SE, et al. Changes in neonatology: comparison of two cohorts of very preterm infants (gestational age <32 weeks): the Project On Preterm and 
Small for Gestational Age Infants [ADDRESS_535353] on Prematurity 
1996- 1997. Pediatrics. Feb 2005;115(2):396- 405. 
9. Hintz SR, Poole WK, Wright LL, et al. Changes in mortality and morbidities among 
infants born at less than [ADDRESS_535354] -surfactant era. Arch Dis Child Fetal 
Neonatal Ed. Mar 2005;90(2):F128- 133. 
10. Wadhawan R, Vohr BR, Fanaroff AA, et al. Does labor influence neonatal and 
neurodevelopmental outcomes of extremely -low-birth-weight infants who are born by 
[CONTACT_27312]? Am J Obstet Gynecol. Aug 2003;189(2):501 -506. 
11. Michael Cotten C, Oh W, McDonald S, et al. Prolonged hospi[INVESTIGATOR_423721]: risk factors, center differences, and the impact of mortality on 
selecting a bes t-performing center. J Perinatol. Oct 2005;25(10):650 -655. 
12. Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of 
extremely low birth weight infants in the National Institute of Child Health and Human 
Development Neonatal R esearch Network, 1993 -1994. Pediatrics. Jun 
2000;105(6):1216 -1226.  
13. Wood NS, Costeloe K, Gibson AT, Hennessy EM, Marlow N, Wilkinson AR. The 
EPI[INVESTIGATOR_66554]: associations and antecedents of neurological and developmental 
disability at 30 months of age fol lowing extremely preterm birth. Arch Dis Child Fetal 
Neonatal Ed. Mar 2005;90(2):F134- 140. 
14. Fily A, Pi[INVESTIGATOR_138064] V, Delporte V, Breart G, Truffert P. Factors associated with 
neurodevelopmental outcome at 2 years after very preterm birth: the population- based 
Nord -Pas-de-Calais EPI[INVESTIGATOR_138065]. Pediatrics. Feb 2006;117(2):357 -366. 
15. Katz-Salamon M, Gerner EM, Jonsson B, Lagercrantz H. Early motor and mental 
development in very preterm infants with chronic lung disease. Arch Dis Child Fetal 
Neonatal Ed. Jul 2000;83(1):F1- 6. 
16. McAleese KA, Knapp MA, Rhodes TT. Financial and emotional cost of 
bronchopulmonary dysplasia. Clinical pediatrics. Jul 1993;32(7):393 -400. 
 ____________________________________________________________________________________________  
51 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
17. Gough A, Spence D, Linden M, Halliday HL, McGarvey L. General and Respi[INVESTIGATOR_423722]: A Systematic 
Review. Chest. Nov 23 2011.  
18. Young TE, Kruyer LS, Marshall DD, Bose CL. Population- based study o f chronic lung 
disease in very low birth weight infants in North Carolina in 1994 with comparisons with 
1984. The North Carolina Neonatologists Association. Pediatrics. Aug 1999;104(2):e17.  
19. Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcom es of the National 
Institute of Child Health and Human Development Neonatal R esearch Network , January 
1995 through December 1996. NICHD Neonatal Research Network. Pediatrics. Jan 
2001;107(1):E1.  
20. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Sil va-Neto G. Changing trends 
in the epi[INVESTIGATOR_423723]. The Journal of 
pediatrics. Apr 1995;126(4):605- 610. 
21. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O'Shea TM. Risk factors for chronic lung disease in the surfactant era: a North Carolina population- based study of 
very low birth weight infants. North Carolina Neonatologists Association. Pediatrics. Dec 
1999;104(6):[ADDRESS_535355] ten days of life and risk of bronchopulmonary dysplasia in extremely low 
birth weight infants. The Journal of pediatrics. Dec 2005;147(6):786- 790. 
23. Ambalavanan N, Van Meurs KP, Perritt R, et al. Predictors of death or 
bronchopulmonary dysplasia in preterm infants with respi[INVESTIGATOR_1399]. J Perinatol. Jun 
2008;28(6):420 -426. 
24. Ryan SW, Nycyk J, Shaw BN. Prediction of chronic neonatal lung disease on day 4 of 
life. European journal of pediatrics. Aug 1996;155(8):668- 671. 
25. Subhedar NV, Hamdan AH, Ryan SW, Shaw NJ. Pulmonary artery pressure: early 
predictor of chronic lung disease in preterm infants. Archives of disease in childhood. 
Jan 1998;78(1):F20- 24. 
26. Romagnoli C, Zecca E, Tortorolo L, Vento G, Tortorolo G. A scoring system to predict 
the evolution of respi[INVESTIGATOR_423724]. Intensive care medicine. May 1998;24(5):476- 480. 
27. Toce SS, Farrell PM, Leavitt LA, Samuels DP, Edwards DK. Clinical and 
roentgenographic scoring systems for assessing bronchopulmonary dysplasia. American 
journal of diseases of children (1960). Jun 1984;138(6):581- 585. 
28. Corcoran JD, Patterson CC, Thomas PS, Halliday HL. Reduction in the risk of 
bronchopulmonary dysplasia from 1980- 1990: results of a multivariate logistic regression 
analysis. European journal of pediatrics. Aug 1993;152(8):677 -681. 
29. Noack G, Mortensson W, Robertson B, Nilsson R. Correlations between radiological and 
cytological findings in early development of bronchopulmonary dysplasia. European 
journal of pediatrics. Dec 1993;152(12):1024- 1029.  
30. Yuksel B, Greenough A, Karani J. Prediction of chronic lung disease from the chest radiograph appearance at seven days of age. Acta Paediatr. Nov 1993;82(11):944- 947. 
31. Bhutani VK, Abbasi S. Relative likelihood of bronchopulmonary dysplasia based on pulm onary mechanics measured in preterm neonates during the first week of life. The 
Journal of pediatrics. Apr 1992;120(4 Pt 1):605 -613. 
32. Kim YD, Kim EA, Kim KS, Pi [CONTACT_244704], Kang W. Scoring method for early prediction of neonatal chronic lung disease using modif ied respi[INVESTIGATOR_108951]. Journal of Korean 
medical science. Jun 2005;20(3):397 -401. 
 ____________________________________________________________________________________________  
52 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
33. Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dysplasia: selection 
criteria for clinical trials. Pediatrics. Nov 1990;86(5):728 -736. 
34. Rozycki HJ, Narla L. Early versus late identification of infants at high risk of developi[INVESTIGATOR_423725]. Pediatric pulmonology. Jun 
1996;21(6):[ADDRESS_535356] Rev. 
2007(4):CD000501.  
36. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. The 
New England journal of medicine. May 18 2006;354(20):2112- 2121.  
37. McCormick A, Suguihara C, Huang J, et al. Depressed ventilatory response to hypoxia in hypothermic newborn pi[INVESTIGATOR_1515]: role of glutamate. J Appl Physiol. Mar 1998;84(3):830 -
836. 
38. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for 
preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 
2009(1):CD001146.  
39. Barrington KJ, Finer NN. Inhaled nitric oxide for preterm infants: a systematic review. 
Pediatrics. Nov 2007;120(5):1088- 1099.  
40. KN S,  Ahlfield SK , Smith PB, Laughon M. Review of randomized controlled trials for the 
prevention of bronchopulmonary dysplasia. ePAS. 2013;1547.651.  
41. Brion LP, Primhak RA, Ambrosio- Perez I. Diuretics acting on the distal renal tubule for 
preterm infants wit h (or developi[INVESTIGATOR_007]) chronic lung disease. Cochrane Database Syst Rev. 
2002 (1):CD001817.  
42. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or 
developi[INVESTIGATOR_007]) chronic lung disease. Cochrane database of systematic reviews. 
2002(1):CD001453.  
43. Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or 
developi[INVESTIGATOR_007]) chronic lung disease. Cochrane database of systematic reviews. 
2011(9):CD001453.  
44. Laughon MM, Chantala K. Aliaga S, et al. Diuretic  Exposure in Premature Infants from 
1997 to 2011. American journal of perinatology. May 6 2014.  
45. Rodriguez W, Selen A, Avant D, et al. Improving pediatric dosing through pediatric 
initiatives: what we have learned. Pediatrics. Mar 2008;121(3):530 -539. 
46. Kearns GL, Abdel -Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 
Developmental pharmacology --drug disposition, action, and therapy in infants and 
children. N Engl J Med. Sep 18 2003;349(12):1157- 1167.  
47. Benjamin DK, Jr., Smith PB, Sun MJ, et  al. Safety and transparency of pediatric drug 
trials. Arch Pediatr Adolesc Med. Dec 2009;163(12):[ADDRESS_535357] 
2014;31(09):811 -822. 
49. Aranda JV, Perez J, Sitar DS, et al. Pharmacokinetic disposition and protein binding of furosemide in newborn infants. The Journal of pediatrics. Sep 1978;93(3):507- 511. 
50. Peterson RG, Simmons MA, Rumack BH, Levine RL, Brooks JG. Pharmacology of furosemide in the premature newborn infant. The Journal of pediatrics. Jul 
1980;97(1):[ADDRESS_535358]. Pharmacokinetics of furosemide in 
neonates. European journal of clinical pharmacology. 1982;22(1):39 -45. 
 ____________________________________________________________________________________________  
53 
NICHD-2014-FUR01  – FUROSEMIDE   Version 6.0 
IND # 120933  22MAR 2017 
 ____________________________________________________________________________________________  
52. Mirochnick MH, Miceli JJ, Kramer PA, Chapron DJ, Raye JR. Furosemide 
pharmacokinetics in very low birth weight infants. The Journal of pediatrics. Apr 
1988;112(4):653 -657. 
 
 
 
 ____________________________________________________________________________________________  
54 